300 related articles for article (PubMed ID: 1517380)
1. A prospective trial of phosphate and 1,25-dihydroxyvitamin D3 therapy in symptomatic adults with X-linked hypophosphatemic rickets.
Sullivan W; Carpenter T; Glorieux F; Travers R; Insogna K
J Clin Endocrinol Metab; 1992 Sep; 75(3):879-85. PubMed ID: 1517380
[TBL] [Abstract][Full Text] [Related]
2. Healing of bone disease in X-linked hypophosphatemic rickets/osteomalacia. Induction and maintenance with phosphorus and calcitriol.
Harrell RM; Lyles KW; Harrelson JM; Friedman NE; Drezner MK
J Clin Invest; 1985 Jun; 75(6):1858-68. PubMed ID: 3839245
[TBL] [Abstract][Full Text] [Related]
3. 24,25 Dihydroxyvitamin D supplementation corrects hyperparathyroidism and improves skeletal abnormalities in X-linked hypophosphatemic rickets--a clinical research center study.
Carpenter TO; Keller M; Schwartz D; Mitnick M; Smith C; Ellison A; Carey D; Comite F; Horst R; Travers R; Glorieux FH; Gundberg CM; Poole AR; Insogna KL
J Clin Endocrinol Metab; 1996 Jun; 81(6):2381-8. PubMed ID: 8964881
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of a role for 1,25-dihydroxyvitamin D3 in the pathogenesis and treatment of X-linked hypophosphatemic rickets and osteomalacia.
Drezner MK; Lyles KW; Haussler MR; Harrelson JM
J Clin Invest; 1980 Nov; 66(5):1020-32. PubMed ID: 6253520
[TBL] [Abstract][Full Text] [Related]
5. Long-term influence of calcitriol (1,25-dihydroxyvitamin D) and supplemental phosphate in X-linked hypophosphatemic rickets.
Chesney RW; Mazess RB; Rose P; Hamstra AJ; DeLuca HF; Breed AL
Pediatrics; 1983 Apr; 71(4):559-67. PubMed ID: 6300745
[TBL] [Abstract][Full Text] [Related]
6. Healing of bone lesions with 1,25-dihydroxyvitamin D3 in the young X-linked hypophosphatemic male mouse.
Marie PJ; Travers R; Glorieux FH
Endocrinology; 1982 Sep; 111(3):904-11. PubMed ID: 6896684
[TBL] [Abstract][Full Text] [Related]
7. X-linked hypophosphatemic rickets: a study (with literature review) of linear growth response to calcitriol and phosphate therapy.
Petersen DJ; Boniface AM; Schranck FW; Rupich RC; Whyte MP
J Bone Miner Res; 1992 Jun; 7(6):583-97. PubMed ID: 1414477
[TBL] [Abstract][Full Text] [Related]
8. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
9. X-linked hypophosphatemia: a clinical, biochemical, and histopathologic assessment of morbidity in adults.
Reid IR; Hardy DC; Murphy WA; Teitelbaum SL; Bergfeld MA; Whyte MP
Medicine (Baltimore); 1989 Nov; 68(6):336-52. PubMed ID: 2811660
[TBL] [Abstract][Full Text] [Related]
10. Familial hypophosphatemic rickets: bone mass measurements in children following therapy with calcitriol and supplemental phosphate.
Block JE; Piel CF; Selvidge R; Genant HK
Calcif Tissue Int; 1989 Feb; 44(2):86-92. PubMed ID: 2492895
[TBL] [Abstract][Full Text] [Related]
11. Parathyroid hormone effects on serum 1,25-dihydroxyvitamin D levels in patients with X-linked hypophosphatemic rickets: evidence for abnormal 25-hydroxyvitamin D-1-hydroxylase activity.
Lyles KW; Drezner MK
J Clin Endocrinol Metab; 1982 Mar; 54(3):638-44. PubMed ID: 6276432
[TBL] [Abstract][Full Text] [Related]
12. The efficacy of vitamin D2 and oral phosphorus therapy in X-linked hypophosphatemic rickets and osteomalacia.
Lyles KW; Harrelson JM; Drezner MK
J Clin Endocrinol Metab; 1982 Feb; 54(2):307-15. PubMed ID: 6976353
[No Abstract] [Full Text] [Related]
13. Comparison of 22-oxacalcitriol and 1,25(OH)2D3 on bone metabolism in young X-linked hypophosphatemic male mice.
Halstead LR; Weinstein RS; Cheng SL; Rifas L; Avioli LV
Am J Physiol; 1996 Jan; 270(1 Pt 1):E141-7. PubMed ID: 8772486
[TBL] [Abstract][Full Text] [Related]
14. Effect of 1,25-dihydroxyvitamin D3 treatment on bone formation by transplanted cells from normal and X-linked hypophosphatemic mice.
Ecarot B; Glorieux FH; Desbarats M; Travers R; Labelle L
J Bone Miner Res; 1995 Mar; 10(3):424-31. PubMed ID: 7785464
[TBL] [Abstract][Full Text] [Related]
15. Therapeutics of X-linked hypophosphatemic rickets.
Latta K; Hisano S; Chan JC
Pediatr Nephrol; 1993 Dec; 7(6):744-8. PubMed ID: 8130097
[TBL] [Abstract][Full Text] [Related]
16. Effects of therapy in X-linked hypophosphatemic rickets.
Verge CF; Lam A; Simpson JM; Cowell CT; Howard NJ; Silink M
N Engl J Med; 1991 Dec; 325(26):1843-8. PubMed ID: 1660098
[TBL] [Abstract][Full Text] [Related]
17. The concurrence of hypoparathyroidism provides new insights to the pathophysiology of X-linked hypophosphatemic rickets.
Lyles KW; Burkes EJ; McNamara CR; Harrelson JM; Pickett JP; Drezner MK
J Clin Endocrinol Metab; 1985 Apr; 60(4):711-7. PubMed ID: 4038714
[TBL] [Abstract][Full Text] [Related]
18. Evidence suggesting hyperoxaluria as a cause of nephrocalcinosis in phosphate-treated hypophosphataemic rickets.
Reusz GS; Latta K; Hoyer PF; Byrd DJ; Ehrich JH; Brodehl J
Lancet; 1990 May; 335(8700):1240-3. PubMed ID: 1971321
[TBL] [Abstract][Full Text] [Related]
19. Bone response to phosphate and vitamin D metabolites in the hypophosphatemic male mouse.
Marie PJ; Travers R; Glorieux FH
Calcif Tissue Int; 1982 Mar; 34(2):158-64. PubMed ID: 6282410
[TBL] [Abstract][Full Text] [Related]
20. X-linked hypophosphatemia: effect of calcitriol on renal handling of phosphate, serum phosphate, and bone mineralization.
Costa T; Marie PJ; Scriver CR; Cole DE; Reade TM; Nogrady B; Glorieux FH; Delvin EE
J Clin Endocrinol Metab; 1981 Mar; 52(3):463-72. PubMed ID: 6893992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
